Evidence map›Paper›PMID 42742941›Full record

ArticleJAMA network open2026

Strategies to Increase Equitable Access to Penicillin Allergy Delabeling Interactions: A Qualitative Study.

Alysse Wurcel, Danielle Crabtree, Olabimpe Asupoto, Madelyn Eippert, Yvane Ngassa, Rachel Tam, Ivana Kohut, Kap Sum Foong, Valerie Stone, Denise Daudelin and 2 more

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alysse WurcelSection of General Internal Medicine, Boston Medical Center, Boston, Massachusetts.
Danielle CrabtreeDivision of Allergy and Clinical Immunology, Massachusetts General Hospital, Boston.
Olabimpe AsupotoDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts.
Madelyn EippertDivision of Pulmonary Allergy and Sleep, Mayo Clinic, Jacksonville, Florida.
Yvane NgassaDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts.
Rachel TamSection of General Internal Medicine, Boston Medical Center, Boston, Massachusetts.
Ivana KohutDivision of General Internal Medicine & Primary Care, Brigham and Women's Hospital, Boston, Massachusetts.
Kap Sum FoongDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts.
Valerie StoneDivision of General Internal Medicine & Primary Care, Brigham and Women's Hospital, Boston, Massachusetts.
Denise DaudelinTufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts.
Stephen BartelsDepartment of Medicine, Harvard Medical School, Boston, Massachusetts.
Kimberly G BlumenthalDivision of Pulmonary Allergy and Sleep, Mayo Clinic, Jacksonville, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Patients with unconfirmed and potentially false penicillin allergy labels receive unnecessarily broad-spectrum antibiotics that can lead to worse health outcomes and antimicrobial resistance. While ambulatory care is a favorable setting to engage in penicillin allergy delabeling, the process of removing an incorrect penicillin allergy label has not been widely implemented. Objective: To contextualize barriers to and facilitators of penicillin allergy delabeling from a diverse range of perspectives and inform actionable strategies. Design, Setting, and Participants: This qualitative study used in-depth interviews and focus groups with patients who had a penicillin allergy label, clinicians, and other stakeholders from primary care clinics in 3 hospital networks in Boston, Massachusetts. Participants were recruited from March 1 through September 30, 2024. Main Outcome and Measures: The primary outcome was participant-perceived factors influencing engagement in discussions about penicillin allergy delabeling. The analytic approach was informed by the updated Consolidated Framework for Implementation Research (CFIR), with a mixed inductive-deductive analysis that incorporated the CFIR Expert Recommendations for Implementing Change (ERIC) implementation strategy matching tool to map interview data to implementation strategies. Results: The study included 119 participants (84 [71%] female), of whom 69 (58%) were patients and 50 (42%) were clinicians and stakeholders; 87 (73%) participated in interviews and 32 (27%) participated in focus groups. Six barriers to penicillin allergy delabeling emerged: (1) clinician avoidance of conversations about penicillin allergy labels, (2) patients not being asked about their penicillin allergy labels, (3) language barriers, (4) time constraints, (5) perceived elevated risk of removing a penicillin allergy, and (6) limited access to allergists. These barriers aligned with 5 ERIC strategies: (1) create new ways of delivering care, (2) identify champions, (3) use data experts, (4) alter incentive structures, and (5) conduct educational meetings. Conclusions and Relevance: This qualitative study guided by implementation science identified strategies to overcome barriers to penicillin allergy delabeling. These strategies may inform the next steps for implementation science research to improve access to penicillin allergy testing and delabeling.

Indexed as

Anti-Bacterial AgentsDrug HypersensitivityPenicillinsAdultAgedBostonFemaleFocus GroupsHumansMaleMiddle AgedQualitative ResearchAnti-Bacterial AgentsPenicillins

Identifiers

PMID42742941
PMCPMC13579434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.